Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients. To accomplish this, we followed an approach comprising structure-based mAb charge engineering in conjunction with the use of relevant preclin...

Full description

Saved in:
Bibliographic Details
Main Authors: Romain Ollier, Aline Fuchs, Florence Gauye, Katarzyna Piorkowska, Sébastien Menant, Monisha Ratnam, Paolo Montanari, Florence Guilhot, Didier Phillipe, Mickael Audrain, Anne-Laure Egesipe, Damien Névoltris, Tamara Seredenina, Andrea Pfeifer, Marie Kosco-Vilbois, Tariq Afroz
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
antibody charge engineering
antibody developability
antibody disposition
Antibody humanization
antibody pharmacokinetics
FcRn transgenic mice
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2232087
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items